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Immune Recovery Uveitis Is Associated with
Th17 Cell Depletion and Poor Systemic CMV-
Specific T Cell Responses
Dennis J. Hartigan-O'Connor,1 Mark A. Jacobson,2 Qi Xuan Tan,1 and Elizabeth Sinclair,1 for the Studies of Ocular
Complications of AIDS Research Groupa
1Division of Experimental Medicine, and 2Positive Health Program, Department of Medicine, University of California, San Francisco; aStudy group
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Background. The immune reconstitution inflammatory syndromes (IRIS) are a spectrum of inflammatory
conditions associated with opportunistic infections and occurring in 16% of human immunodeficiency type 1
(HIV-1)–infected patients given antiretroviral therapy. It has been proposed that these conditions are linked by
a dysregulated immune system that is prone to exaggerated responses. However, immunologic studies have been
limited by the availability of longitudinal samples from patients with IRIS and appropriate matched control subjects.
Cytomegalovirus (CMV) immune recovery uveitis (IRU) is an IRIS occurring in up to 38% of patients with CMV
retinitis. Although the pathologic immune responses occur in the eye, immune dysregulation that allows for
development of pathologic responses is presumably caused by faulty systemic immune cell reconstitution.
Methods. We examined CMV-specific T cell responses, regulatory T (Treg) cell function and polyclonal T cell
responses, including IL-17 production, in 25 patients with CMV IRU and 49 immunorestored control subjects with
CMV retinitis who did not develop IRU.
Results. Patients with CMV IRU had poor CMV-specific CD41 T cell responses, as compared with control
subjects, whereas CD81 T cell responses were comparable. Patients with CMV IRU were characterized by smaller
numbers of circulating Th17 cells. Deficiency in anti-CMV responses was not associated with differences in Treg cell
function.
Conclusions. The Treg cell compartment is intact in patients with CMV IRU, and these patients do not develop
exaggerated systemic CMV-specific or polyclonal immune responses. Cases are instead characterized by more
profound depletion of Th17 cells and poor antiviral immune responses. CMV IRU may be most likely to develop in
persons experiencing the greatest degree of immune dysfunction before initiating highly active antiretroviral therapy.
A subset of patients with AIDS who are immunorestored
with highly active antiretroviral treatment (HAART)
develop inflammatory conditions known collectively as
immune reconstitution inflammatory syndromes (IRIS
[1]). Patients most likely to be affected are those ini-
tiating HAART with low CD4 cell counts and pre-
existing opportunistic infections [1, 2]. The symptoms
of IRIS are often localized to sites of previous infection
[3], and IRIS in patients with a history of cytomega-
lovirus retinitis (CMVR) can manifest as in-
flammation of the posterior uveal tract of the eye [4].
These facts have led to the suggestion that IRIS is
caused by adaptive immune responses to persistent
pathogen-derived antigens [2].
More recently, understanding of the importance
of regulatory T (Treg) cells in controlling immune re-
sponses to self antigens has prompted the suggestion that
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failure to reconstitute Treg cells may predispose to IRIS [5]. We
hypothesized that CMV-specific cytotoxic T lymphocytes are
hyperactive in patients with CMV IRU because of deficiency in
the number or function of Treg cells and that evidence of this
immune perturbation, caused by the immune restoration pro-
cess, would be observed in circulating T cells. To test this hy-
pothesis, we studied Treg cell control over T cell responses in
peripheral blood mononuclear cells (PBMCs) from patients with




Participants gave written informed consent. Guidelines and
standards of the US Department of Health and Human Services
and of University of California, San Francisco, were followed.
The institutional review board of the University of California,
San Francisco, approved the study. Procedures followed were in
accordance with the Helsinki Declaration as revised in 1983.
Patients were immunorestored persons with a documented
history of CMVR who were enrolled in the Longitudinal Study
of Ocular Complications of AIDS (LSOCA) and had a PMBC
specimen available at a time point when active uveitis was
diagnosed by a study ophthalmologist (based on slit-lamp and
dilated funduscopic examination revealing evidence of in-
traocular inflammation). For individuals with newly di-
agnosed IRU, the index visit chosen for study was that when
IRU was first diagnosed, if PBMCs were available, or the next
subsequent visit when PMBCs were available. For patients
with evidence of prior IRU (eg, macular edema), the index
visit chosen was the first subsequent one at which there was
active uveitis and PMBCs were available. For patients with
a newly diagnosed case of CMV IRU, a pre-index visit was
defined as the study visit occurring 3 months before the index
visit. In all pre-index visits, concurrent ophthalmologic ex-
amination revealed no evidence of active uveitis or macular
edema from prior uveitis.
Control subjects were chosen among participants with
a documented history of CMVR who never received a diagnosis
of IRU, were immunerestored by HAART, and had PBMC
specimens available in the LSOCA repository from the same visit
as the patient (61 visit). For each patient, 2 control subjects
were selected, matched to patients by absolute CD41 T cell
count at the time of the index visit, the time interval since
CMVR diagnosis, and duration of LSOCA follow-up.
Samples
Cryopreserved PBMCs were obtained from the LSOCA re-
pository (Thermo Electron, Rockville, MD). Samples with
,50% viability or ,10% recovery were discarded.
Phenotypic Analysis
The frequency of Treg cells was determined by a previously
described phenotypic flow assay [6]. The absolute number of
Treg cells was calculated by multiplying the frequency among
CD41 T cells by the absolute CD4 cell count determined as part
of the LSOCA protocol. FoxP3 is a transcription factor expressed
by natural Treg cells and required for their development [7].
Cytokine Flow Cytometry (CFC)
The fraction of CD41 and CD81 T cells responsive to CMV
pp65 or IE-1 was determined by CFC, as described elsewhere [8].
CD107a is a marker mobilized to the cell surface on de-
granulation of T cells [9].
Treg Functional Assays
Whenever available, PBMC specimens from the 2 subsequent
LSOCA visits after the index visit for each patient and control
subject were used in flow-sorting experiments to test Treg cell
function in suppressing proliferation by other T cells. Specimens
were stained with aqua amine-reactive dye and antibodies
against CD3, CD4, CD25 (IL-2 receptor alpha chain, expressed
by Treg cells [10]), and CD127 (IL-7 receptor alpha chain, not
present on Treg cells [6]). CD3
1CD41CD251CD127low cells
were separated from other cells with use of a FACS ARIA sorter.
Aliquots that were depleted by flow sorting and control aliquots
not depleted (but run through the sorter, to control for physical
effects) were divided into microtiter wells. In additional wells,
sort-purified Treg cells were added back to Treg-depleted cells to
determine whether Treg cells measured in our phenotypic assays
suppressed proliferation and were functional. The cells were
labeled with carboxyfluorescein diacetate succinimidyl ester and
then stimulated with CMV pp65/IE peptides or surface-bound
anti-CD3 antibodies for 5 days.
Statistical Analysis
Plotting and statistical analysis were performed using Stata/IC,
version 10.1 (Stata). Conditional logistic regression was used to
test for differences between the CMV IRU and control groups
that required case-control matching.
RESULTS
Patient Characteristics
Twenty-five LSOCA participants met case criteria, 18 of whom
had newly diagnosed CMV IRU (all had a PBMC specimen
available from the visit when IRU was initially diagnosed). The
index visit was an active recurrence of uveitis for the other 7
patients. Two matched control subjects were found for 24 of the
patients, with 1 control subject for the remaining patient.
Summary statistics for our case and control groups demon-
strate successful matching (Table 1). The median interval be-
tween CMVR diagnosis and CMV IRU diagnosis (ie, index visit)
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was 47.5 months (range, 3–128 months) for those with newly
diagnosed CMV IRU. The median interval between CMVR di-
agnosis and the index visit for those with recurrent uveitis was
112 months (range, 44–180 months). The interval between
CMVR diagnosis and the index visit for control subjects was
within 20% of the matching case interval for 39 of the 49 control
specimens. The historical nadir absolute CD4 cell count docu-
mented before enrollment in LSOCA was 47 cells/lL for control
subjects and 18 cells/lL for patients (P5 .33, byWilcoxon rank-
sum test).
Patients Developing CMV IRU Have Weak Antiviral CD41 T Cell
Responses at Diagnosis
We initially assessed T cell responses in patients and control
subjects at the index visit, when patients had active uveitis. We
hypothesized that differences observed at this time point
could suggest whether systemic T cell responses were related
to the underlying disease immunopathology. Sixteen case-
control sets had evaluable samples from a patient and at least 1
control subject at this time point.
T cells were evaluated for expression of IFN-c, TNF-a, or IL-2
and for mobilization of CD107a after stimulation with CMV
peptide pools. Using a Boolean gating strategy, we obtained data
for 15 possible combinations of cytokine expression and
CD107a mobilization for both CD41 and CD81 T cells. Cells
expressing 6 of these combinations were extraordinarily rare in
the entire dataset and were not analyzed further (typically
,.01%; IL-2 only, IFN-c1TNF-a–IL-21CD107a–, IFN-c–TNF-
a–IL-21CD107a1, IFN-c1TNF-a–IL-2–CD107a1, IFN-c1TNF-
a–IL-21CD107a1, and IFN-c–TNF-a1IL-21CD107a1.)
Analysis of the 9 remaining CD41 T cell populations
demonstrated consistently lower responses in the CMV IRU
Table 1. Subject Participant Characteristics (n 5 74)
Control subjects (n 5 49) Patients with CMV IRU (n 5 25)
P valuesCharacteristic
Mean Mean
Number Percent Number Percent
Age at index visita Mean: 45.9 Mean: 41.5 0.15
,40 years 10 20.4 9 36.0
40–43.99 years 10 20.4 8 32.0
44–48.99 years 14 28.6 5 20.0
>49 years 15 30.6 3 12.0
Race/ethnicity 0.49
White 25 51.0 10 40.0
Black 13 26.5 9 36.0
Hispanic 10 20.4 5 20.0
American Indian 0 0 1 4.0
Other 1 2.0 0 0
Sex 0.19
Male 43 87.8 19 76.0
Female 6 12.2 6 24.0
Prior Cidofovir prescription
Yes 0 0 5 20.0
No 0 0 12 48.0
Unknown 49 100 8 32.0
CD4 cell count,acells/lL Mean: 412 Mean: 410 0.86
,250 12 24.5 7 28.0
250–355 11 22.4 7 28.0
356–502 14 28.6 5 20.0
.502 12 24.5 6 24.0
CD4 cell count, nadir cells/lL Mean: 47 Mean: 18 0.33
Viral load,a logcopies/mL Mean: 2.6 Mean: 2.8 0.52
,1.7 19 38.8 6 24.0
1.7–2.699 14 28.6 10 40.0
2.7–3.3 3 6.1 1 4.0
.3.3 10 20.4 7 28.0
a Measured at the index visit.
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group. The mean sum of these responses, for example, was
1.62% among control subjects and .74% among patients (P 5
.11 by conditional logistic regression; data not shown); the
mean sum of mono- and bifunctional responses was .74%
among control subjects and .28% among patients (P 5 .03;
data not shown). As assessed by IFN-c and TNF-a production
in bifunctional cells, pp65/IE-specific CD41 T cell responses
were significantly lower in patients with CMV IRU than in
control subjects (P 5 .026) (Figure 1A, leftmost panel) this
was true whether responses were assessed as a fraction of
CD41 T cells (Figure 1A) or as an absolute number of cir-
culating cells (Figure 1B). The difference observed was not
restricted to IFN-c and TNF-a production; statistically sig-
nificant differences were also seen in the fraction and/or
number of cells producing TNF-a and CD107a, IFN-c alone,
or TNF-a alone (Figures 1A and 1B, second to fourth panels).
We tested 2-variable conditional logistic models to determine
if production of different cytokine combinations by CD41 T
cells might have independent associations with CMV IRU dis-
ease. We found that these models were not superior to single-
variable models, most likely because of the small number of
evaluable case-control sets (n 5 16) and the near colinearity of
CD41 T cell responses determined using different cytokine
combinations (Figure 1C).
In contrast to CD41 T cells, no statistically significant dif-
ference was observed between patients and control subjects for
any CD81 T cell population. We found this result to be sur-
prising, both in view of data collected by others using a vitreal
sample [11] and because of our expectation that CD41 and
CD81 T cell responses to CMV would be correlated with each
other. In fact, CD41 and CD81 T cell responses to CMV antigen
had no statistically significant association in our dataset (Figure
1D). Furthermore, combinations of CMV-specific CD41 and
CD81 T cell cytokine expression patterns did not discriminate
between patients and control subjects (using cutoff values; data
not shown).
Finally, becauseprior exposure to cidofovir, a drugused to treat
active CMVR, can cause chronic uveitis as an adverse drug effect,
we analyzedourdatasetwhen restricted in eitherof 2 ways (Figure
2): (1) by eliminating 3 patients known to have received cido-
fovir in the past, leaving 13 case-control sets, or (2) by limiting
the data to 7 patients known for certain to have never received
the drug. With use of either restriction, differences between case
and control groups remained significant (Figures 2A and 2B).
Figure 1. Cytomegalovirus (CMV)–specific T cell responses among patients and control subjects at the index visit. A, The fraction of pp65/IE-
specific CD41 T cells among patients with CMV immune recovery uveitis (IRU) or control subjects as assessed by cytokine flow cytometry (CFC) of cell
aliquots from the index visit. The populations shown did not express other cytokines; for example, IFN1TNF1 cells plotted in the figure did not express
IL-2 or mobilize CD107a. Only case-control sets having at least 1 patient and 1 control subject are plotted, and only these sets were analyzed
statistically. The various symbols shown in each dotplot are indicative of matched sets; for example, values for Patient 1 and the associated control
subject(s) are shown with a black circle. The P values shown were calculated using Stata for a conditional logistic regression of CMV IRU status
against the CFC response variable shown on the Y axis, using the case-control set number as the grouping variable. B, The absolute number of cells
producing the indicated cytokines in response to pp65/IE stimulation, in cells per microliter. C, Relationship between 2 different measures of the
CD41 T cell response to virus, IFN-c production and CD107a mobilization. The symbols used for plotting are identical to those used in A and B (ie, all
samples from a specific case-control set are plotted with a shared symbol). D, Relationship between a measure of the CD41 T cell response to virus
and the CD81 T cell response.
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Immune Response Patterns Predictive of CMV IRU before
Diagnosis
Our study was also designed to assess immune responses before
IRU diagnosis, with the goal of identifying immune response
patterns that might be predictive of disease development.
Matched samples from only 7 case-control sets were evaluable in
this analysis. Nevertheless, we again observed a pattern of lower
CD41 T cell responses in patients with CMV IRU, compared
with control subjects. For example, patients with CMV IRU had
a significantly lower fraction and absolute number of cells syn-
thesizing TNF-a and mobilizing CD107a, compared with con-
trol subjects who did not develop the condition (P, .01 in both
cases) (Figures 3A and 3B, middle panels). IFN-c responses were
also lower in patients with CMV IRU, although these differences
did not reach statistical significance (Figures 3A and 3B, left and
right panels).
As was true of samples collected at the index visit, no dif-
ferences in CD81 T cell responses were observed between
patients and control subjects (not shown). Elimination of
case-control sets with patients exposed to cidofovir did not
change the conclusions drawn: P values for the CMV-specific
cell populations shown in Figure 3A were .06, .02, and .04,
respectively.
Treg Control Over CMV-Specific and –Nonspecific T Cells in
Patients with CMV IRU
Although we had initially speculated that patients with CMV
IRU might have fewer or less-functional Treg cells than control
subjects, the data collected using CFC assays (Figures 1– 3)
suggested the alternative possibility—that patients with CMV
IRU might have excessive numbers or functional activity of Treg
cells .
We evaluated numbers of Treg cells at the index and pre-index
visits either as a fraction of CD41 T cells or as an absolute number.
Three Treg cell phenotypes were assessed (CD25
1CD127low,
CD251FOXP31, and CD251CD127lowFoxP31). Data for the
first phenotype are shown in Figure 4A (at the index visit) and
Figure 4B (at the pre-index visit) and show no difference be-
tween patients with CMV IRU and control subjects. Data
Figure 2. Cytomegalovirus (CMV)–specific T cell responses in patients and control subjects not exposed to cidofovir. A, Dotplots for patients who either
did not receive cidofovir or were not known to have received it (n 5 13) and their respective control subjects. From left to right, the dotplots show the
fraction of cells making IFN-c and TNF-a, the fraction making TNF-a and mobilizing CD107a, the number making IFN-c and TNF-a, and the number
making TNF-a and mobilizing CD107a. B, Dotplots for patients known not to have received cidofovir (n 5 7). The left plot shows the fraction of cells
making IFN-c and TNF-a; the right plot shows the absolute number of such cells.
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collected using the 3 different phenotypes were highly inter-
correlated and yielded qualitatively identical results (ie, no
difference between patients and control subjects). Assessment
of the data in terms of absolute circulating cell numbers also
showed no differences.
We next evaluated Treg cell function with use of pro-
liferation assays to test the impact of Treg cell depletion on T
cell proliferation in patients and control subjects. Suppression
of polyclonal responses was assessed using surface-bound
anti-CD3 antibody as the stimulus in wells containing either
intact cell populations or CD31CD41CD251CD127low-de-
pleted populations. Depletion was performed using fluores-
cence-activated cell sorting, to eliminate the possibility that
any suppression observed was attributable to non-Treg cells
that were nonetheless CD251. In this assay, patients and
control subjects exhibited equivalent Treg cell function (Figure
4C). The degree of suppression observed was similar to that of
suppression that we previously observed in chronically HIV-
infected individuals, with many individuals, including pa-
tients with CMV IRU, having little or no suppression attrib-
utable to CD31CD41CD251CD127low Treg cells (data not
shown) (Figure 4C). Only 2 patients of the 14 with CMV IRU
who were tested exhibited unusually robust suppression,
which was confirmed by add-back assays to be caused by
CD31CD41CD251CD127low cells (data not shown)
(Figure 4D).
Figure 3. Cytomegalovirus (CMV)–specific T cell responses in patients and control subjects at the pre-index visit. A, The dotplots show the fraction of
pp65/IE-specific CD41 T cells among patients with CMV immune recovery uveitis (IRU) or control subjects, as assessed by cytokine flow cytometry (CFC)
of cell aliquots from the pre-index visit. Symbols and statistics are as described for Figure 1. B, Dotplots showing the absolute number of cells producing
the indicated cytokines in response to pp65/IE stimulation, in cells per microliter.
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Suppression of CMV-specific T cell responses was tested using
similar methods, except that pp65/IE peptides were used as the
proliferation stimulus. In these assays, patients and control
subjects also exhibited a similar degree of suppression, with
many patients with CMV IRU demonstrating no detectable
suppression (Figure 4E).
Patients with CMV IRU are Characterized by More Profound
Th17 Cell Depletion than are Control Subjects
Several studies have recently demonstrated Th17 cell depletion
from simian immunodeficiency virus–infected nonhuman pri-
mates and HIV-infected persons, the degree of which is predictive
of disease progression [12, 13]. On the basis of the aforementioned
results, we speculated that patients with CMV IRU who have poor
CMV-specific T cell responses might have smaller numbers of
Th17 cells and associated poor antiviral T cell responses.
We found that patients with CMV IRU at the index visit were
indeed characterized by a smaller number of Th17 cells than
were control subjects (Figure 5A). Patients with CMV IRU also
had a lower Th17:Treg cell ratio, a measure that has been used by
some investigators to track Th17 cell depletion (Figure 5B) [12].
At the pre-index visit, in a smaller number of evaluable samples,
no difference in either Th17 cells or the Th17:Treg cell ratio was
observed (data not shown). The Th17 cell population was not
associated with CMV-specific CD41 T cell responses, contrary
to our speculation, but was linearly related to CD81 T cell re-
sponses (Figure 5C). Furthermore, Th17 cells were positively
correlated to Treg cells at both the index (Figure 5D) and pre-
index (Figure 5E) visits.
Th17 cells were identified by measuring IL-17 production
from CD41 T cells after stimulation with anti-CD3 and anti-
CD28, which are both polyclonal stimuli. To determine whether
lower IL-17 production in patients with CMV IRU was attrib-
utable to a generalized loss of cytokine producing cells, we
measured the ability of CD41 T cells to make other cytokines. In
contrast to IL-17 expression, there was no statistically significant
difference in the ability of CD41 T cells from CMV IRU and
Figure 4. Regulatory T cell number and function in patients with cytomegalovirus (CMV) immune recovery uveitis (IRU) and control subjects. A, The
fraction of CD31CD41CD251CD127low regulatory T (Treg) cells present in patients and control subjects at the index visit. Symbols and statistics are as
described for Figure 1. B, The fraction of CD31CD41CD251CD127low Treg cells present in patients and control subjects at the pre-index visit. C,
Percentage suppression of CD41 (left panel) and CD81 (right panel) proliferative responses to stimulation with surface-bound anti-CD3 antibody. Greater
numbers mean more suppression and greater Treg function. These suppression assays were performed using pooled peripheral blood mononuclear cell
(PBMC) samples collected after the index visit. Cells aliquots were assayed either intact or after Treg depletion, as described in Methods, and the
percentage suppression was calculated using the formula: (percent CFSElow in depleted sample-percent CFSElow in undepleted sample)/(percent CFSElow
in depleted sample). D, Example plots demonstrating robust suppression in a patient with CMV IRU. From left to right, the flow cytograms demonstrate
little proliferation in the unstimulated sample, detectable proliferation in the intact sample treated with surface-bound anti-CD3, more robust
proliferation in a Treg-depleted sample, and suppressed proliferation in a sample to which a supraphysiologic number of Treg cells was added. E, Dotplots
showing percentage suppression of CD41 (left panel) and CD81 (right panel) proliferative responses to stimulation with pp65/IE peptides.
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control groups to make IFN-c, IL-2, or TNF-a after stimulation
with anti-CD3 and anti-CD28 (data not shown).
DISCUSSION
We performed a case-control study to test the hypothesis that
development of CMV IRU in immunorestored patients with
AIDS is associated with systemic failure of Treg control over
exaggerated immune responses, reflecting poor reconstitution of
Treg cells. Surprisingly, we found that the number and function
of Treg cells is comparable in patients with CMV IRU and
matched control subjects, both before and after the development
of disease. Furthermore, patients with CMV IRU displayed
weaker anti-CMV CD41 T cell responses than did control
subjects and equivalent virus-specific CD81 T cell responses, as
well as equivalent ability to produce IFN-c, IL-2, and TNF-a
after polyclonal stimulation. This is in contrast to the only other
IRIS for which T cell function before and at the time of IRIS
diagnosis has been investigated. In HIV-infected patients with
active tuberculosis prospectively evaluated when initiating an-
timycobacterial therapy and sequentially during HAART,
a sharp systemic increase in mycobacterial antigen-specific Th1
IFN-c–producing cells (measured by ELISPOT) has been ob-
served in individuals developing tuberculosis IRIS [14]. We
observed no similar explosion in systemic CMV-specific Th1
responses and no diminution of Treg cell numbers or function in
patients with CMV IRU. One possibility is that CMV IRU results
from a heightened sensitivity of lymphopenic hosts to CD41 T
cell responses, as was observed in an animal model of Myco-
bacterium avium immune resonstitution disease [15]. Different
immune mechanisms may underlie the pathogenesis of different
IRIS syndromes, depending on the opportunistic pathogen and,
perhaps, the location of disease.
We also found that patients with CMV IRUwere differentiated
from control subjects by having a smaller number of CD41 Th17
cells, which are not specific for CMV antigens. It has recently
Figure 5. Relationship of Th17 cells to cytomegalovirus (CMV) immune recovery uveitis (IRU) disease, CMV-specific T cells, and regulatory T (Treg) cells .
A, The number of Th17 cells detected in patients and control subjects at the index visit. Symbols and statistics are as described for Figure 1. B, Dotplot
showing the Th17:Treg ratio in patients and control subjects at the index visit. The ratio was calculated by dividing the fraction of Th17 cells among CD4
1
T cells by the fraction of Treg cells (CD3
1CD41CD251CD127low) among CD41 T cells. C, Relationship between Th17 cells, shown on the X axis, and CMV-
specific responses among CD81 T cells, shown on the Y axis. The measure shown is a sum of the fraction of cells found to produce IL-2 alone, TNF-a
alone, both cytokines combined, or both cytokines in combination with IFN-c. D, Relationship between Th17 cells and Treg cells at the index visit. E,
Relationship between Th17 cells and Treg cells at the pre-index visit.
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been recognized that Th17 cells are depleted in simian immu-
nodeficiency virus and HIV disease and that the degree of de-
pletion is predictive of disease progression [12, 13]. We speculate
that lower numbers of Th17 cells among patients with CMV IRU
may reflect greater losses throughout the course of HIV disease
and a correspondingly greater level of immune dysfunction. This
contention is supported by the fact that patients with CMV IRU
had lower absolute CD4 counts at nadir than did control sub-
jects (Table 1), although CD4 cell counts at nadir were not sig-
nificantly predictive of either CMV IRU development or the
size of the Th17 compartment at the index visit (data not
shown). Furthermore, a restricted analysis of case-control sets
in which control nadirs did not exceed case nadirs significantly
(,5 cells/lL) yielded qualitatively identical conclusions to
analysis of the whole dataset. These findings indicate that low
CD4 nadirs themselves do not drive development of CMV IRU.
Although peripheral CMV-specific CD81 T cell responses
were neither predictive of nor associated with CMV IRU, other
researchers have shown that at least some such cells are present
in the eye [11]. Perhaps PBMC immune responses to CMV
antigens other than pp65 and IE correlate with risk for CMV
IRU. Other factors that we did not examine, such as the interval
between initiating anti-CMV therapy and HAART [16] or the
persistence of CMV antigen in the eye [17], might also be im-
portant in CMV IRU pathogenesis.
Nevertheless, our data are congruent with other reports
showing that IRIS is associated with low CD4 cell counts at the
start of antiretroviral therapy [2]. Th17 cell depletion may be
either a reflection or a cause of more general CD41 T cell loss,
whereas severe Th17 cell depletion is associated with disease
progression. Thus, CD4 cell count and Th17 cell number may
both be measures of the severity of HIV disease before initiation
of HAART. Association of these measures with development of
IRIS suggests that the IRIS syndromes are rooted in immune
conditions established at CD4 nadir, rather than failure of the
immune system to re-establish immunoregulatory mechanisms
after immunorestoration.
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